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As a major health issue, obesity is linked with elevated risk of type 2 diabetes. However, whether disrupted
glucose homeostasis is due to altered body composition alone, or whether dietary macronutrients play an
additional role, independent of their impact on body composition, remains unclear. We investigated the
associations betweenmacronutrients, body composition, blood hormones and glucose homeostasis. We fed
C57BL/6Nmice 29 different diets with variable macronutrients for 12 weeks. After 10 weeks,
intraperitoneal glucose tolerance tests were performed. Generalized linear models were generated to
evaluate the impacts of macronutrients, body composition and blood hormones on glucose homeostasis.
The area under the glucose curve (AUC) was strongly associated with body fat mass, but not dietary
macronutrients. AUC was significantly associated with fasting insulin levels. Six genes from transcriptomic
analysis of epididymal white adipose tissue and subcutaneous white adipose tissue were significantly
associated with AUC.These genes may encode secreted proteins that play important previously
unanticipated roles in glucose homeostasis.
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INTRODUCTION
Obesity is one of the most serious global health is-
sues. Excess body weight is the sixthmost important
risk factor contributing to the overall burden of dis-
eases [1]. It increases the risk of many chronic dis-
eases, including type 2 diabetes, cardiovascular dis-
eases, hypertension, stroke and cancer [1]. Obesity
is one of the main risk factors for impaired glucose
homeostasis and type 2 diabetes [2], and is widely
agreed to stem from prolonged energy imbalance
[3]. A major contributor to this imbalance is excess
energy intake rather than low energy expenditure
[4].
Changingmacronutrient composition in the diet
may promote energy intake and therefore impact
adiposity, however, there is still debate over whether
high fat (HF), high sugar, low protein or all three are
responsible for the elevated intake [5–8]. It is also
uncertain to what extent disrupted glucose home-
ostasis, and other features of poor metabolic health
in individuals with obesity, are a consequence of ele-
vated body weight and adiposity alone, or whether
macronutrient composition of the diet is an addi-
tional or the sole factor of importance.
Some evidence supports the idea that adi-
posity is not responsible by itself for the features
of metabolic dysfunction. For example, there is
a subgroup of people who have obesity yet are
metabolically healthy, so called ‘fat yet fit’ indi-
viduals [9], and also individuals who are normal
weight, but with dysfunctional metabolic status
[10]. These individuals are possibly explained
by differing dietary macronutrient compositions
and energy intakes that underpin their weight
status [9,10]. Moreover, in individuals that are
overweight or with obesity as well as type 2 dia-
betes, glucose levels improve rapidly when energy
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intake is decreased, even before weight loss [11].
Glucose tolerance improves rapidly following
bariatric surgery, also often in advance of significant
weight loss, in both mice and humans [12,13].
Body weight loss and reduced energy intake can
further improve metabolic syndrome and fatty
liver, including improved insulin sensitivity, blood
glucose and lipid control [14,15].
Some studies, focusing on specific diets with
high/lowprotein, fat or carbohydrate, have reported
impacts of different diets on glucose tolerance and
fasting glucose/insulin levels in rodents [16–23].
Yet in many of these studies, only two or three
diets were investigated in each study, and the dif-
ferent diets with variable compositions provided in-
consistent results. More comprehensive dietary ma-
nipulations including larger numbers of diets have
been performed [8,23] but these have not included
glucose tolerance tests (GTTs). Moreover, in a pre-
vious study where a large dietary matrix was used
and GTTs were performed, this study did not at-
tempt to partition the effects of diet directly on the
GTT from the impacts mediated via body weight
[24]. It is consequently still unclear how macronu-
trients impact glucose homeostasis in animals, and
whether the effects on glucose homeostasis are di-
rect or mediated via body composition. Therefore,
we designed 29 different diets varying orthogonally
in their macronutrient compositions to separate dif-
ferentmacronutrient effects, and then fed these diets
to C57BL/6Nmice for 12 weeks [8].We previously
explored the impact of these diets on food intake and
body weight regulation [8]. In the present study the
objectivewas to investigate the effects of dietary pro-
tein, fat and sucrose content on glucose homeosta-
sis; specifically to explore the associations between
dietarymacronutrients, body fatmass, leanmass and
fasting blood glucose (FBG) levels and the area un-
der the curve (AUC) of the standard intraperitoneal
glucose tolerance tests (ipGTT) using generalized
linear modeling (GLM).
RESULTS
Dietary protein content does not affect
fasting glucose levels and glucose
tolerance in mice
Body mass and fat mass of the mice increased grad-
ually during 12 weeks on the diets with variable pro-
tein content and either 60% or 20% fat (Fig. S1).
The increase in body mass was mainly due to the
increase in fat mass (Fig. S1). No significant differ-
ence was observed in the fat mass of the mice fed
diets with variable protein content and either fixed
20% (ANOVA, F5, 52 = 1.891,P= 0.112) or 60% fat
(ANOVA, F5, 53 = 0.941, P = 0.463). There was no
significant difference in lean mass between the mice
fed diets with different protein contents, except sig-
nificant differences between 5% and 20% protein at
60% fat (ANOVA, F5, 53 = 2.573, P = 0.037), and
between 5% and 25% protein at 20% fat (ANOVA,
F5, 49 = 3.005, P= 0.019).
IpGTT were performed to investigate the glu-
cose tolerance in mice fed on diets with variable
protein content. Fasting glucose levels were mea-
sured before glucose injection. There was no sig-
nificant difference in FBG in mice fed diets with
60% fat (ANOVA, F5, 48 = 1.283, P = 0.287), and
only significantly lower FBG levels in the mice fed
with 5% protein than 20% protein without any dif-
ference between other groups when dietary fat was
fixed at 20% (ANOVA, F5, 50 = 2.656, P = 0.033)
(Fig. 1). AUC over the 2 h following glucose injec-
tion was not significantly different in themice fed on
diets with variable protein contents and either fixed
20% (ANOVA, F5, 55 = 1.129, P = 0.356) or 60%
fat (ANOVA, F5, 55 = 1.802, P = 0.128) (Fig. 1).
Overall these results demonstrated that dietary pro-
tein levels between 5% and 30% had no appreciable
effect on glucose homeostasis.
Dietary fat content affects fasting
glucose levels and glucose tolerance
in mice
Similarly, body mass, fat mass and lean mass of the
mice all increased gradually in mice fed diets with
variable fat content and fixed 10% or 25% protein
content (Fig. S2). Increased body mass was mainly
from increased body fat mass rather than lean mass
(Fig. S2). In themice fed the fixed 10%protein diets,
bodymass (ANOVA, F5, 52 = 3.007, P= 0.019) and
fat mass (ANOVA, F5, 52 = 2.632, P = 0.034) were
significantly different between the diets with 10%
and 50% fat, but there were no differences among
other diets with variable fat content. Significant dif-
ferences were observed in body mass (ANOVA,
F5, 52 = 14.805, P = 5.054 × 10−9) and fat mass
(ANOVA, F5, 56 = 22.356, P = 3.011 × 10−12) in
mice fed with variable fat and fixed 25% protein con-
tent after 10weeks feeding.Therewere no significant
differences in lean mass of all mice fed on diets ei-
ther with 10% (ANOVA, F5, 52 = 1.440, P= 0.226)
or 25% dietary protein (ANOVA, F5, 54 = 1.522,
P= 0.199) (Fig. S2).
In the ipGTT, no significant difference was
observed between any groups in both FBG levels
(ANOVA, F7, 68 = 2.310, P = 0.036, overall signif-
icance) and AUC of the glucose curve (ANOVA,
F7, 70 = 0.731, P = 0.646) of the mice fed on diets
with fixed 10% protein and variable fat content
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Figure 1. Glucose tolerance test of the mice fed on diets with fixed 60% fat or 20% fat and variant protein content. Ten mice
per diet were used. Values were presented as mean ± SD. Glucose curve of the mice fed on diets with fixed 60% fat (A) or
20% fat (B) over 2 hours. (C) Fasting blood glucose levels. (D) Area under the glucose curve (AUC). See also Fig. S1.
(Fig. 2). Significantly different FBG levels
(ANOVA, F7, 73 = 10.429, P = 6.004 × 10−9) and
AUC of the glucose curve (ANOVA, F7,75 = 4.987,
P= 1.13× 10−4) were observed in the mice fed on
diets with fixed 25% protein and variable fat content
(Fig. 2). Both FBG levels and AUC of the glucose
curve were significantly higher in the mice fed on
diets with fixed 25% protein content and 41.7% or
higher fat content, with no significant differences
when fat content was between 8.3% and 33.3%
(Fig. 2).The results suggest chronic exposure tohigh
fat diets (more than 41.7% fat) impaired glucose
tolerance.
Dietary sucrose content does not impact
glucose tolerance in mice
To investigate the effect of dietary sucrose on glu-
cose homeostasis, we then fixed both fat (41.7%)
and protein (25%) and only changed sucrose con-
tent (5%–30%) in the diets. Body mass, fat mass
and leanmasswere all increased gradually during the
experimental period in the mice fed on these diets
(Fig. S3). Body mass was gained mainly from fat
mass, consistent with the changes observed in the
other 24 diets (Fig. S3). There was no significant
difference in body mass (ANOVA, F5, 24 = 0.407,
P = 0.839), fat mass (ANOVA, F5, 24 = 0.413,
P= 0.835) and lean mass (ANOVA, F5, 24 = 1.237,
P=0.323)between themice fedondietswith differ-
ent sucrose content after 10 weeks feeding. No dif-
ferencewas observed in either FBG levels (ANOVA,
F5, 24 = 1.567, P = 0.207) or AUC of the glucose
curve (ANOVA, F5, 24 = 0.867, P= 0.517) between
the mice fed on diets with variable sucrose content
(Fig. 3), demonstrating no extra effect of high su-
crose (HS) on glucose tolerance.
GLM analysis of AUC of the glucose
curve and FBG levels
A GLM was performed to explore the association
between the AUC and body fat mass, lean mass,
dietary protein and fat contents. There were no
significant interactions (P > 0.05) and no effect
of lean mass, and therefore these variables were
removed and a revised model generated (AUC-
GLM1). In the revised model, body fat mass was
significantly related to AUC (P < 0.0001). How-
ever, neither dietary protein (P = 0.335) nor
fat (P = 0.666) content had effects on AUC of
the glucose curve. Fat mass explained 38.8% of
the variation in AUC across the individual mice
(Fig. 4A).
Similarly, a GLM was also performed to explore
the association between FBG and body fat mass,
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Figure 2. Glucose tolerance test of the mice fed on diets with fixed 10% protein or 25% protein and variant fat content. Nine
to eleven mice per diet were used. Values were presented as mean ± SD. Glucose curve of the mice fed on diets with fixed
10% protein (A) or 25% protein (B) over 2 hours. (C) Fasting blood glucose levels of the mice on diets with 10% protein. (D)
Fasting blood glucose levels of the mice on diets with 25% protein. (E) Area under the glucose curve (AUC) of the mice on
diets with 10% protein. (F) AUC of the mice on diets with 25% protein. See also Fig. S2.
dietary protein and fat contents. Body fat mass, lean
mass and dietary protein or fat all had no interaction
effects (P>0.05), and leanmass hadno effect on the
FBG levels (P = 0.880). Therefore, we revised the
GLM by removing these non-significant terms. The
final GLM (FBG-GLM1) demonstrated that both
body fat mass (P < 0.0001) and dietary fat content
(P= 0.003) were significantly related to FBG levels,
but dietary protein content showedno significant as-
sociation (P = 0.405). The model explained 40.1%
of the variation in FBG levels, with body fat mass ex-
plaining 38.6% of the variation (Fig. 4B).
GLMbydefinitiononly detects linear effects, and
non-linear relationshipsmay in theory exist between
the FBG levels or AUC and each of the co-variates.
To examine if there were any non-linear effects be-
tweenFBG levels orAUCagainst body fatmass, lean
mass, dietary proteinor fat,we analyzed the residuals
from the GLMs, and plotted these residuals against
body fat mass and dietary fat content (Fig. S4). The
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Figure 3. Glucose tolerance test of the mice fed on diets with fixed 25% protein and
41.7% fat and variant sucrose content. Five mice per diet were used. Values were
presented as mean ± SD. (A) Glucose curve over 2 hours. (B) Fasting blood glucose
levels. (C) Area under the glucose curve (AUC). See also Fig. S3.
gradients of the linear regressionmodels of the plots
were −3.0 × 10−15 and 1.0 × 10−14, respectively,
for AUC, and −1.0 × 10−10 and −3.0 × 10−10, re-
spectively, for fasting glucose levels (P > 0.05 in all
cases), suggesting there were no non-linear effects
on either FBG levels or AUC.
As a separate experiment in thedietswith variable
sucrose content, aGLMwas generated for bothFBG
and AUCof the glucose curve against body fat mass,
leanmass anddietary sucrose content.Noneof these
terms were significantly associated with either FBG
levels orAUCof the glucose curve.Therewas also no
potential non-linearity in the relationships (Fig. S5).
Blood insulin levels were associated
with both FBG levels and AUC of the
glucose curve, but leptin was only
associated with FBG levels
The dominant impact of the dietary macronutrients
on glucose homeostasis were mediated by their im-
pacts on body fatness, rather than via direct effects
of the diets themselves. The impacts of expanding
fat tissue may be mediated in part by hormones that
are related to the levels of body fatness. We there-
fore turned our attention towards the roles played
by hormones that are linked to body fatness in me-
diating this association. Fasting blood hormone lev-
els, including insulin, leptin and IGF-1, were mea-
sured. All three hormones were significantly posi-
tively correlated to body fat mass (P= 3.59× 10−6
for insulin, P = 3.09 × 10−9 for leptin, P = 0.001
for IGF-1) (Fig. 4C–E). Significantpositive relation-
ships were also observed between circulating hor-
mone levels and FBG (F1, 22 = 40.883, P = 1.96 ×
10−6 for insulin; F1, 22 = 53.132, P = 2.67 × 10−7
for leptin; F1, 22 = 9.084, P = 0.0064 for IGF-1)
and AUC (F1, 22 = 33.296, P = 8.35 × 10−6 for
insulin; F1, 22 = 15.845, P = 6.30 × 10−4 for lep-
tin; F1, 22 = 5.184, P = 0.033 for IGF-1) (Fig. 5).
These results suggest that the impact of body fatness
on glucose homeostasis was at least partially medi-
ated through these hormones. We also excluded the
potential non-linear relationships by examining the
patterns of residual variation against the hormones
(Fig. S6).Homeostaticmodel assessment for insulin
resistance (HOMA-IR) were also calculated for the
24 diets, and plotted against dietary fat content or
body fat mass. The results were almost identical to
that in Fig. 2C and D and Fig. 4 (data not shown).
GLM was then used to explore the associations
between insulin, leptin, IGF-1 and FBG levels or
AUCof the glucose curve.Therewere no interaction
effects between insulin, leptin and IGF-1 (P> 0.05),
and therefore we removed all the interaction terms.
The revised GLMs (AUC-GLM2 and FBG-GLM2)
showed that only insulin was significantly associated
with AUC of the glucose curve (P = 0.001), and
both insulin (P = 0.006) and leptin (P = 0.001)
were significantly associated with FBG levels.
According to the above results, body fat mass
was associated with glucose homeostasis poten-
tially mediated partly by insulin and leptin levels.
Therefore, an AUC-GLM (AUC-GLM3) was gen-
erated against body fat mass, insulin and leptin lev-
els, to check if body fat mass has an additional
effect on AUC apart from the effects via insulin
and leptin. This analysis showed that body fat mass
(P = 4.61 × 10−6) was still significantly associated
with AUC, while insulin (P= 0.207) and leptin lev-
els (P= 0.093) were no longer significant.This sug-
gests that apart from an effect of body fat on glu-
cose homeostasis mediated partly through insulin
and leptin, body fat mass probably also significantly
impacted glucose homeostasis through additional
pathway(s). Similarly, an FBG-GLM(FBG-GLM3)
was also generated against body fat mass, dietary fat
content, insulin and leptin levels.The results showed
that all terms were not significantly associated with
FBG, suggesting no additional factors/pathways im-
pacted FBG apart from body fat mass, dietary fat
content, insulin and leptin levels.
We then extracted the residuals from AUC-
GLM2 with insulin as co-variate and FBG-GLM2
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FBG vs body fat




















AUC vs body fat
Body fat vs insulin 
Body fat vs IGF-1
Body fat vs leptin
Y = 0.2220×X + 4.263
R2 = 0.3855
Figure 4. Linear regression between area under the glucose curve (AUC) or fasting
blood glucose and body fat mass, or between body fat mass and blood hormone lev-
els. Values were individual measurements for each mouse. (A) AUC. (B) Fasting blood
glucose. (C) Insulin. (D) Leptin. (E) IGF-1. See also Fig. S4.
with insulin and leptin as co-variates, respectively,
to quantify the effect of body fat on the residuals.
As body fat mass had a significant effect on both the
AUCandFBG levels fromprevious analysis, we then
plotted the residuals from both GLMs against body
fat mass, respectively (Fig. S7). As shown in AUC-
GLM3, body fat mass was still significantly associ-
ated with AUC, and it explained 9.4% of the varia-
tion of residuals from theAUC-GLM2excluding the
effect of insulin and leptin. Only 4.0% of the varia-
tionwas explainedby fatmass in the linear regression
model against the residuals from the FBG-GLM2, as
there were no additional effects of body fat on FBG
from FBG-GLM3 (F1, 22 = 0.92, P= 0.348).
Expression of genes in the epididymal
white adipose tissue and subcutaneous
white adipose tissue correlated to the
residuals from AUC-GLM and FBG-GLM
Transcriptomic analysis of both epididymal white
adipose tissue (eWAT) and subcutaneouswhite adi-
pose tissue (sWAT) revealed expression of 18,202
identified genes. We calculated the correlations be-
tween residuals from the GLM of either AUC or
FBG against blood hormone levels and each of the
genes.The results revealed 73 genes in eWATwhose
geneexpression levelswere correlatedwith the resid-
uals from the GLM with AUC against blood hor-
mone levels, but no gene expression levels were
correlated with the residuals from the GLM of
FBG against blood hormone levels (for full list see
TableS1). For the sWAT, therewere115genesposi-
tively correlated to the residuals from theGLMwith
AUC against blood hormone levels (for full list see
Table S1). Moreover, 14 of the 115 genes were pos-
itively correlated with the residuals from the GLM
with FBG against blood hormone levels.
Adipose tissues secrete a large number of pro-
teins (adipokines), which may play key roles in reg-
ulating glucose homeostasis in animals. We then as-
sessed if the 73 positively correlated genes in the
eWAT and 115 positively correlated genes in the
sWAT encode proteins with a signal peptide, indi-
cating that they may be secreted proteins. In the
eWAT, 31 out of 73 genes encode signal peptides,
while 27 out of 115 genes in the sWATencode signal
peptides. To further investigate the potential roles
of these genes encoding signal peptides in glucose
homeostasis, we then assessed the associations be-
tween each of these genes and the AUC of the glu-
cose curve. The results showed that 2 of 31 genes in
the eWAT and 11 of the 27 genes in the sWATwere
directly and significantly associatedwith the AUCof
the glucose curve.
Since both body fat mass and these genes poten-
tially play important roles in both FBG levels and
the AUC of the glucose curve, we explored the rela-
tionship between these genes and body fat mass.We
then performed regression analysis between body
fat mass and the identified genes encoding signal
peptides (31 genes from eWAT and 27 genes from
sWAT).Therewere 11 of 31 genes in the eWAT and
9 of 27 genes in the sWAT significantly associated
with body fat mass.
We then compared the two genes from eWAT
and 11 genes from the sWAT (which were signifi-
cantly associatedwith theAUCof the glucose curve)
with the 11 genes from the eWAT and nine genes
from the sWAT (which were significantly associ-
ated with body fat mass). The results showed that
one gene from eWAT and five genes from sWAT
were significantly and directly associated with both
body fat mass and the AUC of the glucose curve.
These genes were Tmem119 (transmembrane pro-
tein 119), Cpa2 (carboxypeptidase A2), Optc (op-
ticin), Lrrc15 (the type I transmembrane pro-
tein 15-leucine-rich repeat containing membrane
protein), Tril (TLR4 interactor with leucine-rich
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Y = 134×X + 1326
R2 = 0.60
Y = 18×X + 1394
R2 = 0.42
Y = 5.3×X + 1470
R2 = 0.19
Y = 0.035×X + 5.3
R2 = 0.29
Y = 0.13×X + 4.7
R2 = 0.71
Y = 0.74×X + 4.7
R2 = 0.65
Figure 5. Linear regression between area under the glucose curve (AUC) or fasting
blood glucose and blood hormone levels. Values were mean values for each diet group.
(A, B) Insulin. (C, D) Leptin. (E, F) IGF-1. See also Fig. S6.
repeats) and Ptprk (Protein tyrosine phosphatase
receptor type kappa). The six genes were then re-
gressed to AUC and AUC residuals from the GLM,
respectively. Expression of all six genes showed a
positive relationshipwith bothAUCandAUCresid-
uals (Fig. 6).AnotherGLM(AUC-GLM4)was then
generated against body fat mass, insulin, leptin lev-
els, plus the six gene expression levels. Expression of
the Tmem119 gene was still significantly associated
with AUC (P= 0.011), while body fat mass, insulin
and leptin levels, and the other five gene expression
levels were all not significant (P> 0.05).This shows
that body fat mass may impact glucose homeosta-
sis in mice through the effect of insulin, leptin and
mechanisms related to these five genes.The effect of
the five genes on glucose homeostasis may be part of
the effect of body fat. Tmem119 may play a role on
glucose homeostasis through an unknown pathway
independent of body fat.
DISCUSSION
We designed 29 diets varying orthogonally in
their macronutrient compositions and exposed
C57BL/6N mice to these diets for 12 weeks. We
investigated the changes in body mass, fat mass and
lean mass and their impacts on glucose homeostasis
(FBG and AUC) after 10 weeks of diet intervention.
Variation in protein levels (between 5% and 30%)
and sucrose levels had no effect on both FBG levels
and AUC. The main impact on FBG and AUC was
due to body fatness which explained 38.8% of the
variation in AUC and 38.6% of the variation in
FBG. Dietary fat content explained an additional
1.5% of the variance in FBG. Fasting blood insulin,
leptin and IGF-1 levels were all positively associated
with body fat mass of the mice, and also positively
associated with both FBG levels and AUC of the
glucose curve.
Previous studies have suggested that carbohy-
drate intake may play a role in glucose homeostasis
[15].Glucose tolerance is a function of glucose stim-
ulated insulin secretion, hepatic glucose output and
tissue insulin sensitivity [25]. In rats, a HS (30% in
solution) and high fat diet (HFD) induced glucose
intolerance (both fasting glucose and AUC) after
13 weeks [16]. HF (45%) and HS (50%) diets
caused different types of glucose intolerance inmice,
probably due to peripheral insulin resistance in HF
fed mice and reduced early insulin secretion in HS
fed mice, respectively [17]. C57BL/6 mice fed an
HFD (23.7% fat and 53.3% carbohydrate) devel-
oped glucose intolerance as early as after threeweeks
compared to a diet with 13% fat and 60% carbohy-
drate [18]. HF and low carbohydrate diets caused
impaired glucose tolerance in mice [19] and rats
[20]. The effect of dietary protein on glucose tol-
erance in animals has also been reported, yet the
results were inconsistent [21–24]. In rats, 35% di-
etary protein and 20% fat impaired glucose toler-
ance probably due to the high level of saturated di-
etary fat [21], while high protein (52%) and low fat
(9%) diet improved glucose tolerance [22]. How-
ever, a high (60%) protein and low carbohydrate
diet significantly impaired glucose tolerance, and led
to higher insulin levels and homeostatic model as-
sessment (HOMA) values in mice after eight weeks
feeding, in comparison with medium (33%)/low
(5%) protein and medium/high carbohydrate diets,
with fixed 20% fat in all three diets [23].
Most of these previous studies have focused
on comparing only two or three diets. More-
over, in many cases the composition of these di-
ets is not ideal for separating the impacts of dif-
ferent macronutrients because the compositions of
the specific macronutrients are confounded by dif-
ferences in other components. Furthermore, few
studies have attempted to separate whether the
impacts on glucose homeostasis stem from di-
etary effects or are mediated via impacts on body
composition.
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Y = 1.260×X + 1385
R2 = 0.5202
Y = 10.94×X + 1437
R2 = 0.4569
Y = 6.722×X - 160.8
R2 = 0.4338
Y = 1.418×X + 1440
R2 = 0.2700
Y = 0.7647×X - 190.1
R2 = 0.4818
Y = 1.164×X - 211.9
R2 = 0.4575
Y = 0.8799×X + 1088
R2 = 0.6905
Y = 0.4085×X - 283.5
R2 = 0.3742
Y = 0.4766×X + 1192
R2 = 0.7160
Y = 0.2310×X - 245.3
R2 = 0.4228
Y = 0.4716×X + 1328
R2 = 0.6477
Y = 0.2332×X - 183.2
R2 = 0.3982
Figure 6. Linear regression between area under the glucose curve (AUC) and AUC
residuals and the expression levels of six genes. Values were mean values for each
diet group. (A) Cpa2. (B) Optc. (C) Lrrc15. (D) Ptprk. (E) Tril. (F) Tmem119.
In our study increased dietary protein content
did not lead to a decreased body fat mass, which dif-
fered from a previous study suggesting high protein
diets improved glucose tolerance in rats due to re-
duced fat mass [22].The discrepancy between stud-
iesmaybe themuchhigher levels of protein (52%) in
their diets. Another large dietarymanipulation study
investigated 25 diets in 858mice and reported some
different outcomes from the present study [24]. In
the previous study, high-protein diets reduced food
intake when protein intake was over 10 kJ/day [24],
in contrast to our diets where both food intake and
energy intake were not changed when dietary pro-
tein content increased from 15% to 30% and pro-
tein intake was above 10 kJ/day. As we discussed
previously, there was a difference in the range of
the protein content, 5%–30% protein in our diets
and 5%–60% in their diets [8,24]. In their study
mice were fed with the experimental diets at three
weeks old, while in our study mice were not ex-
posed to the experimental diets until 10 weeks of
age [8,24].Themetabolism of nutrients inmice dur-
ing early life [26,27] and old age [24] is different
from that which takes place during adult life. There
might be an early life developmental effect of mice
in their study, which was not discussed as the re-
ported results were collected between six months
and 15months of age [24]. By contrast, in our study
mice had the same background diets until they were
switched to experimental diets at 10 weeks old. A
GTT was performed at 15 months of age, which is
late middle age, in their study [24], however, it was
performed at about five months of age in our study.
Overall, the two studies represent different nutri-
tional metabolism of mice at different stages of their
life.
Previously, HS diets were suggested to impair
glucose tolerance in rats andmice [16,17]. Although
we recently reported that higher liquid sucrose in-
take impaired glucose tolerance response in mice,
this effect was more likely due to the higher body
weight and body fatness than the higher absolute
sucrose intake [28]. There might be differences be-
tween mice strains, mice and rat, sucrose delivery
mode or even differences in the microbiome com-
position across animal housing conditions at differ-
ent places. The mice developed glucose intolerance
when fed on diets with high fat content, indepen-
dent of carbohydrate content, consistent with pre-
vious studies [17–20]. These studies suggested that
increased body mass, body fat mass and lean mass
were likely related to the impaired glucose tolerance
[17–20].
Blood insulin levels were associated with both
FBG and AUC, while leptin was only associated
with FBG levels. AUC-GLM3 showed a significant
association between body fat mass and AUC, sug-
gesting a significant additional effect of body fat
mass on glucose tolerance apart from an effect po-
tentially mediated via insulin and leptin, and body
fat mass explained 9.4% of the residual effect from
AUC-GLM2. This low percentage variation might
be because that genes expressed in fat that are only
loosely linked to the amount of fat mass. In longi-
tudinal studies, higher fasting insulin levels reduced
the subsequent body weight gain [29,30]. Also, it
was reported that there was a causal effect of adi-
posity on increasing fasting insulin level [31]. Leptin
levels were also previously correlated with body fat
mass [32].
The six genes expressed in adipose tissue that we
identified as linked to theAUCare likely tobepoten-
tial genes that play important roles in glucose home-
ostasis, andmayunderpin the additional role of body
fat mass in glucose control. None of the genes have
been previously reported as potential genes mediat-
ing thedirect linkof obesity todiabetes. Importantly,
Tmem119 [33] and Ptprk [34,35] are involved in
TGF-β signaling. Blocking of the TGF-β signaling
pathway induces browning of the white adipose tis-
sue [36,37], and systematic blockade protects mice
fromobesity, diabetes and hepatic steatosis and thus
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may be a therapeutic strategy for obesity [36,37]
and diabetes [36]. The TGF-β signaling pathway
has also been associated with type 2 diabetes risk
in genome-wide association studies (GWAS)
[38,39]. Therefore, Tmem119 and Ptprk may play
important roles in the development of obesity and
diabetes. In addition, protein tyrosine phosphatases
receptors have been associated with glucose home-
ostasis in mice (Ptprs and LAR) [40,41] and with
type 2 diabetes risk in GWAS (Ptprd) [42]. Ptprd,
Ptprs and LAR belong to R2A subtype, and Ptprk
is the R2B subtype of PTP, which are very close
subtypes [43], and thus Ptprk may also have the
potential to impact glucose regulation. Cpa2 is
one of the three carboxypeptidases secreted from
the pancreas in the form of inactive precursors
known as procarboxypeptidases [44]. Cpa2 is
expressed in rat pancreas [45], and at extremely low
abundance in the brain and several other extrapan-
creatic tissues such as the lung and testis (about four
orders of magnitude lower than in the pancreas)
[46]. Cpa2 has not previously been described from
adipose tissue. It is a known secreted peptide which
exerts carboxypeptidase activity preferentially at
the 3’ end of target proteins. Lrrc15 [47], Tril
[48] and Optc [49] all have leucine rich repeats.
A recent paper suggested that leucine rich repeat
domain proteins may interact with protein tyrosine
phosphatase receptor type kappa (PTPRK) protein,
which links to TGF-β signaling [50].
In conclusion, we observed a significant effect of
body fat on glucose homeostasis by affecting both
FBG levels and glucose clearance after a glucose
challenge. Only dietary fat content impacted FBG
levels, but not glucose clearance. As we have re-
cently reported [9], dietary fat content regulates
body fat mass in mice. Therefore, we propose that
dietary fat content impacts glucose homeostasis in
mice mainly through its effect on body fat mass,
with a small direct effect on FBG levels. The as-
sociation between body fat and glucose homeosta-
sis may be partly mediated through blood insulin
and leptin, as well as pathways linked to six iden-
tified genes in white adipose tissue. In particular,




All procedures were reviewed and approved by
the Institutional Review Board, Institute of Genet-
ics and Developmental Biology, Chinese Academy
of Sciences (approval numbers AP2014011 and
AP2016039).
Mice and experimental diets
C57BL/6N male mice were purchased at age eight
weeks from Charles River. The number of mice
across all experiments was 300. The mice were ex-
posed to 29 different diets with varying macronu-
trient contents (Table S2, which updates previous
table [9]).
Body mass, food intake and body
composition measurements
Body mass and food intake were measured daily.
Body composition including fat mass and lean mass
were measured weekly using an EchoMRITM Body
Composition Analyzer. Canola oil was used as the
standard.
Intraperitoneal glucose tolerance test
An ipGTT was performed 10 weeks after diet expo-
sure. Following overnight fasting, glucose (2 g/kg
body mass) was injected IP following measurement
of fasting glucose. Blood (2–3μL) was obtained by
a tail prick at 15, 30, 60, 90 and 120min, and glucose
concentrations were measured using a glucometer.
The total area under the glucose concentration-time
curve (AUC) was calculated over 2 h following
glucose injection.
Blood hormone measurements
Following clotting, blood samples were centrifuged
(3500 rpm, 30 min) to separate serum. Serum lep-
tin, insulin and IGF-1 levels were determined using
Mouse Leptin ELISA kit (90 030), Ultra-Sensitive
Mouse Insulin ELISA kit (90 080) and Mouse
IGF-1 ELISA kit (80 574) (Crystal Chem Inc., US),
respectively. Five individuals were randomly chosen
for each diet group, and mean values of each group
were used for linear regression with body composi-
tion and AUC.
RNA sequencing (epididymal and
subcutaneous white adipose tissue)
From each diet group, the sWAT and eWAT of
12 individuals were collected. Each diet group had
onepooled sWATsampleof sixmice andonepooled
eWAT sample of the other six mice. Total RNA
was extracted using RNeasy Mini Kit (QIAGEN,
74 104). RNA sequencing was performed using the
Illumina NextSeq 500 sequencer as reported [9].
Genes with counts per million (CPM) values≥ 1 in
at least one diet group were retained.
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Biological interpretation
The CPM values for genes from the eWAT and
sWAT were correlated with the residuals of gener-
alized linear models with AUC or FBG against hor-
mone levels.The significant genes were then aligned
with the Uniprot database to explore whether they
encode signal proteins. Genes encoding a signal
peptide were considered for further analysis. Step-
wise regression andGLMswere performed between
AUC and insulin levels andCPMvalues of genes en-
coding signal peptides. CPM values of these genes
were then regressed to AUC and AUC residuals of
the GLMs.
Statistical analysis
Statistics were performed using IBM SPSS 20,
GraphPad Prism 6.0 and Microsoft Excel. All
values are expressed as mean ± SD. One-way
ANOVA with Bonferroni post hoc testing was
performed. Differences were considered significant
if P< 0.05. The GLM was performed to relate FBG
or AUC to body fatness and dietary macronutri-
ents or hormone levels. Residuals were exported
from the GLMs, and then associated with related
parameters.
SUPPLEMENTARY DATA
Supplementary data are available atNSR online.
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